Aura Biosciences (AURA) Free Cash Flow (2020 - 2026)

Aura Biosciences has reported Free Cash Flow for 7 years, with the latest figure at -$29.9 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 27.06% year-over-year to -$29.9 million; the trailing twelve-month figure through Mar 2026 stood at -$91.6 million (down 16.18% YoY), and the FY2025 full-year result was -$85.2 million, down 6.7% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$29.9 million, down from -$20.6 million in the prior quarter.
• The five-year high for Free Cash Flow was -$10.5 million in Q2 2022, with the low at -$29.9 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$18.5 million across 5 years, with a median of -$17.5 million in 2022.
• Annual changes were most pronounced in 2022 — Free Cash Flow sank 203.36% — and 2025, when it rose 10.37%.
• Aura Biosciences' Free Cash Flow stood at -$17.5 million in 2022, then dropped by 3.29% to -$18.0 million in 2023, then fell by 27.74% to -$23.0 million in 2024, then increased by 10.37% to -$20.6 million in 2025, then sank by 44.89% to -$29.9 million in 2026.
• The last three Free Cash Flow figures came in at -$29.9 million (Q1 2026), -$20.6 million (Q4 2025), and -$20.2 million (Q3 2025), per Business Quant data.